Eprosartan: Difference between revisions

Eprosartan
Clinical data
Pregnancy; category	?;
Routes of; administration	Oral
ATC code	C09CA02 (WHO) ?;
Legal status
Legal status	?;
Pharmacokinetic data
Bioavailability	?
Metabolism	?
Elimination half-life	5 to 9 hours
Excretion	?
Identifiers
	IUPAC name 4-[[2-butyl-5-(2-carboxy-3-thiophen-2-yl-prop-1-enyl)- imidazol-1-yl]methyl]benzoic acid;
CAS Number	133040-01-4;
PubChem CID	9670;
DrugBank	APRD00950;
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
Formula	C23H24N2O4S
Molar mass	Eprosartan mesylate: 520.625 g/mol

VisualWikitext

Revision as of 02:20, 9 August 2012

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

For patient information, click here

Overview

Eprosartan is an angiotensin II receptor antagonist used for the treatment of high blood pressure. It is marketed as Teveten® by the Biovail Corporation in the United States and by Solvay Pharmaceuticals elsewhere. It is sometimes paired with hydrochlorothiazide.

The drug acts on the renin-angiotensin system in two ways to decrease total peripheral resistance. First, it blocks the binding of angiotensin II to AT₁ receptors in vascular smooth muscle, causing vascular dilatation. Second, it inhibits sympathetic norepinephrine production, further reducing blood pressure.

As with other angiotensin II receptor antagonists, eprosartan is generally better tolerated than enalapril (an ACE inhibitor), especially among the elderly.^[1]

References

↑ Ruilope L, Jäger B, Prichard B (2001). "Eprosartan versus enalapril in elderly patients with hypertension: a double-blind, randomized trial". Blood Press. 10 (4): 223–9. PMID 11800061.

External links

Teveten (manufacturer's webdite)
Eprosartan (patient information)

Template:Angiotensin II receptor antagonists

Template:WikiDoc Sources

[1] Ruilope L, Jäger B, Prichard B (2001). "Eprosartan versus enalapril in elderly patients with hypertension: a double-blind, randomized trial". Blood Press. 10 (4): 223–9. PMID 11800061.

[1]

@@ Line 21: / Line 21: @@
 {{CMG}}
 __NOTOC__
-{{Editor Join}}
 ==[[Eprosartan (patient information)|For patient information, click here]]==

Clinical data

Pregnancy category	?
Routes of administration	Oral
ATC code	C09CA02 (WHO) ?
Legal status
Legal status	?
Pharmacokinetic data
Bioavailability	?
Metabolism	?
Elimination half-life	5 to 9 hours
Excretion	?
Identifiers
IUPAC name 4-[[2-butyl-5-(2-carboxy-3-thiophen-2-yl-prop-1-enyl)- imidazol-1-yl]methyl]benzoic acid
CAS Number	133040-01-4
PubChem CID	9670
DrugBank	APRD00950
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
Formula	C₂₃H₂₄N₂O₄S
Molar mass	Eprosartan mesylate: 520.625 g/mol